Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of TQC3927 inhalation powder in patients with chronic obstructive pulmonary disease
CTR20262190Phase 2Active
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQC3927 in chronic obstructive pulmonary disease (COPD), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Jun 2026; status: active.
02
Drugs
TQC3927
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20262190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262190.